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ABSTRACT 
The treatment objectives for a patient with Cushing’s disease (CD) are remission of hypercortisolism, 
adequate management of co-morbidities, restoration of the hypothalamic-pituitary-adrenal axis, 
preservation of fertility and pituitary function, and improvement of visual defects in cases of 
macroadenomas with suprasellar extension. Transsphenoidal pituitary surgery is the main treatment 
option for the majority of cases, even in macroadenomas with low probability of remission. In cases 
of surgical failure, another subsequent pituitary surgery might be indicated in cases with persistent 
tumor imaging at post surgical magnetic resonance imaging (MRI)  and/or pathology analysis of 
adrenocorticotropic hormone-positive (ACTH+) positive pituitary adenoma in the first procedure. 
Medical treatment, radiotherapy and adrenalectomy are the other options when transsphenoidal 
pituitary surgery fails. There are several options of medical treatment, although cabergoline and 
ketoconazole are the most commonly used alone or in combination. Novel treatments are also 
addressed in this review. Different therapeutic approaches are frequently needed on an individual 
basis, both before and, particularly, after surgery, and they should be individualized. The objective of 
the present review is to provide the necessary information to achieve a more effective treatment for 
CD. It is recommended that patients with CD be followed at tertiary care centers with experience in 
treating this condition. Arch Endocrinol Metab. 2018;62(1):87-105
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INTRODUCTION
C ushing’s syndrome is associated with a high mortality risk (1-10). A meta-analysis has found 
a standardized mortality ratio (SMR) of 2.22 (range, 
1.45 – 3.41; confidence interval, CI, 95%) in patients 
with Cushing’s syndrome compared to the general 
population (7). The major causes of mortality in these 
patients are cardiovascular diseases (ischemic heart 
disease and cerebrovascular diseases), diabetes mellitus 
(secondary to hypercortisolism), and infections (due to 
immunosuppression). 
Clearly, the mortality rate is influenced by the disease 
activity. The SMR is higher in patients with persistent 
disease when compared to patients in clinical remission 
of the hypercortisolism: 5.50 (range, 2.69 – 11.26) vs. 
1.20 (range, 0.45 – 3.18), respectively (7).
Nevertheless, even after the resolution of 
hypercortisolism, there may not be a complete 
reversal of cardiovascular risk factors or, alternatively, 
a complete reversal may take more than 5 to 6 years 
to occur (8,11,12). In addition, patients with active 
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life and lower scores might persist even after surgical 
remission (13).
One factor contributing to the onset and progress 
of associated co-morbidities is the time spent since the 
recognition of the disease, its diagnostic confirmation 
(involving complex and expensive laboratoty and 
imaging studies), and correct definition of the etiology 
(1,14-17). Accordingly, a recent study showed 
increased mortality in patients with longer exposure to 
hypercortisolism (8). 
Thus, to improve the prognosis of patients with 
Cushing’s syndrome and to help reverse morbidities, 
it is important to identify the disease and to achieve 
eucortisolism as soon as possible. 
The objective of the present review is to provide 
the necessary information to achieve a more effective 
treatment of CD. The specific therapeutic approach 
of the several co-morbidities associated with CD is 
beyond the scope of this review. The present manuscript 
highlights the importance of centers of excellence with 
a highly experienced multidisciplinary team for long-
term follow-up of these patients
TREATMENT
The goals of the treatment of CD are as follows: 
(i) remission of hypercortisolism, (ii) adequate 
management of co-morbidities and cardiovascular 
risk factors, (iii) restoration of the hypothalamic-
pituitary-adrenal axis, (iv) preservation of fertility and 
maintenance of pituitary function and (v) improvement 
of visual defects in cases of macroadenomas with 
suprasellar extension. However, it is common that one 
or more objectives need to be sacrificed to achieve 
remission in a patient (18).
Although surgical treatment generally results 
in high remission rates at short term in series from 
specialized centers (~70-80%), recurrence is observed 
in a substantial proportion of patients who then need 
other therapies to control hypercortisolism. 
Surgical treatment
Despite advances in drug treatment and progress 
in other therapeutic modalities, such as stereotactic 
radiotherapy, surgical treatment is still the principal 
definitive treatment for CD (19).
Some recommendations regarding the preoperative 
management of patients with CD should be taken 
into account. Due to a higher risk of cardiovascular 
complications, such as coronary heart disease, it is 
important to conduct a careful cardiac assessment 
of these patients. However, the risk stratification 
does not differ from that in individuals without 
Cushing’s syndrome. There is also increased risk of 
thromboembolic events, both pre- and postoperatively 
(PO) (20-25). Thus, the analysis of coagulation 
factors is very important, although there are no formal 
guidelines to define which factors should be analyzed 
in addition to those traditionally considered (i.e., 
thrombin time, prothrombin time, thromboplastin 
activated time, platelets) or which coagulation protocol 
should be recommended before and after surgery 
(26). In patients treated with antiplatelet drugs (to 
prevent ischemic events), antiplatelet therapy should be 
withdrawn at least seven days before surgery. 
Usually, drug treatment for hypercortisolism 
is unnecessary during the preoperative period. 
Nevertheless, in some cases, it is necessary to initiate 
a specific medical treatment during the preoperative 
period, for instance, in patients with more severe disease 
and increased preoperative risk and when surgical 
treatment can not be immediately performed. The 
most commonly used approach is therapy with adrenal 
steroidogenesis inhibitors, particularly ketoconazole, 
which has a shorter half-life than the dopaminergic 
agonist cabergoline, which acts on corticotroph tumors 
and causes less interference with cortisol measurements 
during the PO period (27). 
Many factors influence transsphenoidal surgery 
remission rates, including characteristics of the pituitary 
adenoma (e.g., tumor size, location, extension, 
aggressiveness, histological type and radiological 
identification), surgical procedure (e.g., the quality 
of the equipment and surgical technique), variability 
of the remission criteria used, and, particularly, the 
surgeon (e.g., experience, surgical identification of the 
tumor) (28).
All factors mentioned above contribute to the wide 
range of PO remission rates reported on by numerous 
case studies. In general, the mean remission rate ranges 
from 70% to 90% in several reviews (19,27,29,30). 
However, within the same case series, the remission 
rate may vary, depending on the subset of the patient 
analyzed, e.g., whether patients had a micro or a 
macroadenoma, whether tumor was identified on 
preoperative pituitary magnetic resonance imaging 
(MRI) or during surgery; and whether patients had 
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petrosal sinus sampling (BIPSS). Importantly, 
recurrence may occur several years later.
In cases of macroadenoma (≥ 10 mm), the remission 
rate ranges from 50% to 70% (27) and is generally 
lower than the microadenoma remission rate (19). 
These percentages can vary depending on the size and, 
particularly, the degree of invasion of the adenoma 
into the adjacent tissues. A study performed on a small 
sample (n = 40) identified tumor size as the main factor 
responsible for post surgical remission rate. The authors 
observed remission rates of 84% for microadenomas 
(21/25), 92% for macroadenomas (11/12; mean of 15 
mm; only 2 with invasion) and no remission for patients 
without visible tumor during surgery (n = 3) (31).
The remission rate in patients submitted to BIPSS is 
also lower than that observed in visible microadenomas 
on MRI and ranges from 50% to 70% (27,32). 
Interestingly, a study that specifically assessed remission 
in these cases did not show any difference between 
positive and negative MRI findings (33). In this subset, 
the main factor influencing remission rate was the 
intraoperative identification of the tumor. 
Other predictive factors of a better surgical 
outcome include absence of invasion of the duramater 
or cavernous sinuses, histological confirmation of 
adrenocorticotropic hormone-positive (ACTH+) 
adenoma, low serum cortisol levels during the PO 
period, and prolonged secondary adrenal insufficiency 
(> 12 months) (27).
In pediatric patients, the number of reported cases 
is lower, but remission rates are similar or slightly 
increased in some cases, ranging from 83% to 98% 
(34,35). A recent study identified histopathology with 
an ACTH+ pituitary adenoma and no invasion as early 
predictors of remission in children. Young age, smaller 
tumors and no invasion of duramater or cavernous 
sinuses were predictive of long-term remission (35). 
Almost all patients undergo pituitary surgery 
via transsphenoidal endonasal approach, including 
those with macroadenoma (29,30). Craniotomies 
are the exception and are indicated in rare selected 
cases. The most studied is the microscopic technique, 
but the endoscopic approach has been increasingly 
used in the last decade. The remission rate is similar 
for both techniques, particularly in the case of 
microadenomas (30,36-40). For macroadenomas 
and invasive tumors, the endoscopic technique has a 
potential advantage in offering a greater angular field 
of view, and therefore visualizing and removing tumors 
impinging the cavernous sinus or extending beyond 
the sellar boundaries. Other techniques that can 
improve intraoperative tumoral localization, such as 
ultrasonography, neuronavigation, rapid pathological 
and/or hormonal analysis and intraoperative MRI, 
are not available in most centers and therefore their 
usefulness cannot be properly evaluated so far. 
Adenomectomy is the most performed surgery, 
although exploration of the entire gland is justified in most 
cases. In patients with no identified tumor, an ipsilateral 
hemi-hypophysectomy (partial hypophysectomy) is 
usually performed in the side suggested by BIPSS with 
lower remission rates. Total hypophysectomy is rarely 
justified due to a limited remission rate in such cases 
and expected hypopituitarism (27). 
Pituitary surgery has a low mortality rate (0% 
to ≤ 1.5%), (29,41) comparable to the outcomes 
observed in simpler surgical procedures. The most 
common complications are endocrine: transient 
diabetes insipidus in 3% to 9% of patients (polyuria 
and/or hypernatremia), hyponatremia that can result 
from secondary adrenal insufficiency, particularly 
in patients not taking glucocorticoids, or syndrome 
of inappropriate antidiuretic hormone secretion 
(SIADH), and other pituitary deficiencies (growth 
hormone deficiency, hypogonadotropic hypogonadism, 
central hypothyroidism). Other complications 
include cerebrospinal fluid fistula (< 8%), bleeding 
or hematomas (range, 1-6%), epistaxis, infections 
(particularly sinusitis), and thromboembolic events 
(29). Due to the risk of thromboembolic events, it is 
recommended to perform active prophylaxis, including 
pneumatic compression of the lower limbs, low-
molecular-weight heparin treatment as soon as possible 
(24h after surgery), and early mobilization during the 
hospital stay. However, there is no current specific 
anticoagulation protocol for Cushing’s disease. The 
rates of complications derived from microsurgery and 
endoscopic techniques are similar. 
Criteria for remission, glucocorticoid replacement 
therapy, and prediction of recurrence risk
Several clinical and laboratory criteria are used to 
define PO remission, but there is no consensus or 
ideal method that guarantees a recurrence-free follow-
up period (29). However, a patient who develops 
adrenal insufficiency with very low serum cortisol 
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replacement therapy clearly exhibits PO remission. 
However, these “rigid” laboratory criteria are not 
found in up to 20% of patients who show long-term 
remission and exhibit “normal” PO cortisol levels (42). 
Other factors used to define post surgical remissions 
are reversal of hypercortisolism, need of glucocorticoid 
replacement therapy and normalization of cortisol 
parameters, particularly urinary free cortisol (UFC) 
lasting at least 6 months after surgery. 
Adrenal insufficiency is not clear in all cases, 
particularly when early glucocorticoid replacement 
therapy is routinely performed or in previously treated 
patients who undergo surgery and who exhibit 
eucortisolism. The symptoms that indicate adrenal 
insufficiency are asthenia, appetite loss, nausea, 
skin peeling, joint and muscle pain, weight loss, low 
blood pressure and/or postural hypotension. Mild 
hyperthermia, a transient increase in TSH levels, and 
hyponatremia might also occur. Although ACTH 
also stimulates aldosterone secretion, it should be 
highlighted that severe hypotension and hyperkalemia 
are not common due to the integrity of the renin-
angiotensin-aldosterone system. 
The most studied and utilized laboratory parameter 
is serum cortisol. In a recent guideline, a cortisol level 
< 5 µg/dL in the first PO week was stated as indicative 
of remission (19). Other authors have attempted to 
identify a more accurate “ideal” cortisol level (43). 
However, it is known that even undetectable levels 
of serum cortisol are not a guarantee of long-term 
remission (44), and an important study observed 
recurrence in 20% of patients at 5 years, even among 
those with cortisol levels < 2 µg/dL (45). Thus, 
more important than determining an “ideal value” 
is to understand that there are different levels of 
recurrence associated with serum cortisol values, as 
follows: < 2, low risk; 2 – 5, intermediate risk; > 5 µg/
dL, high risk (46). Another important finding is that 
5.6% of patients present a gradual decline in cortisol 
levels after the first week (“late remission”) (47). For 
this reason, other cortisol samples must be collected, 
particularly during the first PO month. The two most 
cited explanations for this fact are the persistence of 
cortisol secretion due to chronically stimulated adrenal 
glands and the subsequent post surgical necrosis of 
corticotropic tumor cells. Interestingly, one study has 
shown increased long-term recurrence in patients from 
this late remission subgroup (47). 
A very important factor for the analysis of serum 
cortisol levels in the PO period is glucocorticoid 
replacement therapy. Generally, two replacement 
strategies have been used and they do not include 
glucocorticoids during anesthetic induction. In one 
strategy, routine replacement therapy is not performed 
during the immediate PO period and in the initial 
days. Despite the short half-life of cortisol (range, 
50–70 minutes) and intense reduction of its serum 
concentration after a successful adenoma removal, the 
patient does not usually show adrenal insufficiency 
too early – 24-48 hours – after surgery (48-50). Thus, 
the measurement of morning cortisol or a 6/6-hour 
curve starting in the immediate PO period is performed 
during the first days, and glucocorticoid replacement 
is initiated only after suggestive symptoms of adrenal 
insufficiency (with measurement being performed 
immediately before) and/or when low levels of cortisol 
are detected (< 5 µg/dL). Endocrinologists should 
closely assess the patient, if possible, until replacement 
is initiated. In this strategy, one advantage is that serum 
cortisol measurements are not influenced by exogenous 
corticosteroids. The second strategy consists of 
initiating routine glucocorticoid replacement therapy 
during the immediate PO period, preferably with short 
half-life corticoids, such as hydrocortisone (immediate 
PO, 25–50 mg intravenously three times per day), 
followed by oral hydrocortisone (from the 1st PO 
day forward: 20 mg early in the morning, 10 mg at 
2 PM). In this way, serum cortisol measurements 
are performed only in the morning from 8 to 9 AM 
on any given day, under fasting condition, 18 to 24 
hours after the last dose. The main advantages of this 
strategy are (i) easy applicability; (ii) patient safety; (iii) 
a lower incidence of adrenal insufficiency symptoms, 
although relative adrenal insufficiency can still occur 
with replacement therapy; (iv) reduced suppression of 
the hypothalamic-pituitary-adrenal axis (good for the 
pediatric population) compared with longer half-life 
drugs, such as prednisone or dexamethasone; and (v) 
easy measurement of serum cortisol, which allows the 
physician to observe the progressive increase of serum 
cortisol levels along with the recovery of the axis, which 
occurs 6 to 18 months PO. 
However, although it is the most used glucocorticoid 
in this clinical setting, hydrocortisone is commercialized 
in Brazil in just one tertiary center (hydrocortisone, 20 
and 5 mg tablets). The advantage of using dexamethasone 
(dose: 0.25 – 1 mg once daily; tablets with 0.5, 0.75 
and 4 mg) is that it does not usually interfere with the 
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used in some centers (29). However, due to its longer 
half-life, even when used at low doses, it is not possible 
to exclude the suppression of the axis, potentially 
leading to underestimated cortisol levels. The only 
advantage of prednisone (dose: 2.5 – 5 mg once daily; 
tablets, 5 and 20 mg) is the diffuse availability of the 
product; however, this drug can cause interference 
with the cortisol measurement and may suppress the 
axis with chronic use, although the risk of suppressing 
the axis is lower when compared to dexamethasone. 
Prednisone should be withdrawn at least 48 h before 
serum and/urine cortisol measurements, leading to an 
increased need of observation for the risk of adrenal 
insufficiency. Recently, another form of oral dual-
release hydrocortisone has been studied in patients with 
adrenal insufficiency (51). However, there is no data 
on advantages of these formulations in this subgroup 
of PO patients with CD in order to normalize the 
hypothalamic pituitary adrenal axis. 
In addition to serum cortisol, other laboratory 
criteria have been used, albeit infrequently, to define 
short-term remission (40). Among these criteria are 
lower than normal UFC (47), lower than normal 
plasma ACTH (52) and cortisol suppression after a low 
dose of dexamethasone (15).
Among these parameters, ACTH measurement 
is currently the most studied and is primarily used to 
predict the risk of long-term recurrence (49,53). A 
study that analyzed patients in initial PO remission 
(serum cortisol < 3 µg/dL) showed lower PO ACTH 
in patients with long-term remission compared to 
those with recurrent disease (11.9 vs. 34.3 pg/mL, p < 
0.0001, respectively) (49). 
One study investigated late-night salivary cortisol 
and found this parameter to be more accurate in 
predicting PO remission in comparison to serum 
cortisol and UFC (54). Late-night salivary cortisol was 
measured starting from 6 months PO. Further studies 
are necessary to show the utility of this method in 
assessing initial remission. However, there are studies 
showing a good utility of this method for earlier 
diagnosis of recurrence, even before the UFC (55,56). 
Other methods are used to predict the risk of 
long-term recurrence. Primary among these methods 
are measurements of ACTH or cortisol following 
administration of corticotropin-releasing hormone 
(CRH) (46), metyrapone, thyrotropin-releasing 
hormone (TRH), luteinizing hormone-releasing 
hormone (LHRH), loperamide and desmopressin. 
The rational of these tests derives from the incapacity of 
normal corticotropes, suppressed by hypercortisolism, 
to secrete ACTH. In this way, early PO responses suggest 
the presence of residual tumor cells and, consequently, 
an increased risk of recurrence. The response to 
desmopressin is the most used test, with several studies 
showing similar results (57-64). One of the major 
problems with this test is the definition of ACTH and 
cortisol responses after desmopressin administration 
in the PO period. Several authors have used criteria 
similar to those used in the preoperative period (i.e., 
serum cortisol increased by > 20% and ACTH increased 
by > 30% to 50%) (57-61,63,64). These definitions, 
however, may overestimate any observed increase; for 
example, a change in serum cortisol from 1 to 2 µg/dL 
could correspond to an increase of 100%. A previous 
study assessed the risk of recurrence if the variation of 
serum cortisol is > 7 µg/dL (variation (Δ): peak minus 
time 0) after IV desmopressin 10 µg administration 
approximately 2 weeks PO. This method had a 
specificity of 100% and a sensitivity of 33%. It should be 
noted that in this previous study, only patients with low 
serum cortisol (< 6 µg/dL approximately 6 days PO) 
were subjected to the test, excluding patients with a risk 
of recurrence due to increased PO cortisol levels (62). 
Another factor to be kept in mind as associated to lower 
risk of recurrence is the higher length of postoperative 
glucocorticoid replacement, such as more than 12 
months (41). 
Surgery following initial surgical failure
After an initial surgical failure, the clinical case must 
be entirely reviewed. A diagnosis of CD should be 
confirmed by histopathological examination of the 
pituitary adenoma, which should be ACTH-positive on 
immunohistochemistry. If no adenoma has been found 
and the pituitary gland is reported as normal, then the 
diagnosis might be confirmed through PO remission 
or through the central to peripheral ACTH gradient 
at BIPSS. BIPSS might be performed with the sole 
objective of confirming a central origin not yet proven, 
considering that lateralization cannot be trusted to 
predict tumor localization. Another important issue is 
the description of the surgery as reported or registered 
by the surgeon. For example, a report of partial 
tumor resection due to invasion of the cavernous 
sinus in a macroadenoma patient limits the indication 
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pituitary adenoma is also important in deciding upon 
a new pituitary surgical procedure. This should be 
evaluated with a new pituitary MRI performed at least 
3 months after transsphenoidal surgery showing a 
residual tumor (65). These aspects need to be carefully 
analyzed before referring patients for another pituitary 
surgical procedure, especially if the first operation was 
not performed by an experienced surgeon (29). The 
remission rate is lower than observed for the first 
surgery, ranging from 40% to 70% (27,66,67), a rate 
that is similar to that obtained with current medical 
treatment. In addition, it is important to highlight that 
the rate of complications, including cerebrospinal fluid 
fistula and hypopituitarism, is higher when compared 
to the first surgery. 
Some authors recommend early re-operation at 
3 to 15 days after initial surgical failure, defined by 
serum cortisol > 2 µg/dL (53,68-70). However, as 
late remission can occur in 5.6% of patients 30 to 50 
days after the initial surgery (47), this strategy is not 
commonly used.
Medical treatment
Medical treatment can be classified as primary or 
secondary. Primary therapy is used to lower cortisolemia 
and improve preoperative clinical conditions, or in 
cases of surgical contraindication or refusal, or before 
other definitive approaches. Secondary treatment 
after surgical failure is much more common, and is 
indicated for patients with relapse and no indication 
for a new surgery, as well as in patients who undergo 
pituitary radiotherapy. The drugs are classically divided 
into three classes: a) acting on the ACTH-secreting 
tumor, b) adrenal steroidogenesis inhibitors, and c) 
cortisol receptor antagonists. The first two classes 
comprise several drugs, some of which are currently in 
use and several others are not available or are under 
development. The limited number and availability of 
these drugs reflect the difficulty of controlling cortisol 
levels in CD patients. No ideal treatment is available, 
as reviewed in several recent articles (18,22,23,71-80). 
Drugs acting on the corticotropic tumor 
Cabergoline
Due to the very frequent expression of dopaminergic 
subtype 2 receptors (DRD2) on the surface of tumor 
cells in several types of pituitary adenomas, dopamine 
agonists, particularly cabergoline, have been used 
to treat prolactinomas (first option), acromegaly 
(adjuvant), clinically non-functioning adenomas and 
CD (adjuvant). 
A study on corticotropic tumors elegantly 
demonstrated the expression of DRD2 in more than 
80% of tumor samples, which exhibit binding affinity 
and in vitro inhibition of ACTH secretion in response 
to dopamine agonists (50). 
For the treatment of CD, bromocriptine was 
initially used with limited efficacy and common side 
effects due to the need of high doses (range, 3.75 – 
30 mg). Thus, the use of bromocriptine is no longer 
justified. Cabergoline, a better-tolerated and more 
potent and specific DRD2 receptor agonist, has been 
assessed for efficacy in some studies (50,81-85). UFC 
normalization, the primary endpoint for most studies, 
was observed in 25 – 40% of the 72 patients analyzed 
(4 studies with at least 10 cases), with mean dose of 
3 mg/week (range, 1 – 7) and an average treatment 
period of 18 months (range, 3 – 60) (50,81-83). No 
long-term response predictor has been identified and 
there have been few cases studying the correlation 
between the in vivo response and DRD2 receptor 
tumor expression (50). The efficacy of cabergoline 
declines with increasing treatment duration, an effect 
that is primarily due to tachyphylaxis, which occurs due 
to unknown mechanisms and is observed in 18 – 30% 
of cases (81,82), even with prolonged use (1 – 5 years) 
(81,82). Cabergoline therapy is usually initiated at 1 
mg/week (0.5 mg twice per week, at night; tablets, 
0.5 mg), with a monthly increase of 1 mg if UFC 
normalization does not occur. One study defined 
unresponsiveness as a reduction in UFC lower than 25% 
after 3 months of treatment with increasing doses (81). 
A reduction in tumor size/volume was poorly assessed 
in previous studies. A reduction of at least 25% of the 
tumor size occurred in 50% of cases in one study (81), 
although case reports have demonstrated significant 
reductions (86,87). There is a recommendation for 
monitoring cardiac valves by echocardiogram during 
cronic use of cabergoline due to potential risk of 
thickening described with larger doses of cabergoline 
in Parkinson’s patients (88). However, there are no 
data on echocardiographic changes after prolonged 
use in Cushing´s patients. Finally, although studies 
have shown the effectiveness of cabergoline in a subset 
of patients with CD, its use is off-label, and it is not 
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Pasireotide
The first-generation somatostatin analogues octreotide 
and lanreotide, traditionally used to treat patients with 
acromegaly, are not indicated for the treatment of CD 
due to the low expression of the subtype 2 somatostatin 
receptor (SSTR2) as a consequence of down regulation 
by hipercortisolism in corticotrope tumors (89,90). 
The development of new somatostatin analogues 
with a different affinity profile to SSTR subtypes has 
opened new therapeutic possibilities. Pasireotide is 
the first specific drug approved for the treatment of 
CD in Europe, USA and recently in Brazil (ampules 
for subcutaneous use: 300, 600 and 900 mg). In 
comparison to first-generation somatostatin analogues, 
pasireotide has increased affinity to SSTR1 (> 30 
times), SSTR3 (> 3 times) and, particularly, SSTR5 
(> 40 times) (27), which is the most expressed receptor 
in tumor corticotropes (91). This new analogue has 
been tested both in vitro (92,93) and in vivo studies 
(94). The core study employed in the pasireotide 
approval was published in 2012 (95). This was a 
prospective, multicenter, double-blind study on the use 
of pasireotide in patients with persistent or recurrent 
CD or naïve patients who could not undergo surgical 
treatment. Two doses were tested (600 or 900 µg 
SC twice per day) for 12 months, and a total of 162 
patients were assessed. A significant UFC reduction (at 
least > 50%, primary endpoint) was observed in 49% of 
patients at 6 months, with UFC normalization in 28.8% 
of patients who were treated with 900 µg of pasireotide, 
a response that was maintained up to 12 months with 
no relapses during this period. A subsequent extension 
study showed a similar and sustained response after 
24 months (96) and even in longer studies up to 72 
months (73,91,97). 
The therapeutic response to pasireotide depends 
on the intensity of hypercortisolism. Complete 
response was noted in 50% of patients with baseline 
UFC up to twice the upper limit versus 8% in those 
with baseline UFC > 5 times the upper limit (95). In 
addition, an early response at 2 to 3 months predicted 
a sustained response at 12 months. Parameters such 
as weight, blood pressure, lipid profile and quality 
of life improved in patients with reduced UFC, even 
when normalization was not achieved. An analysis of 
tumor volume was performed in a subset of patients 
and showed a reduction of 43.8% (compared to initial 
volume) at 12 months in patients who are treated with 
900 mg. Side effects were very common and similar to 
those of other somatostatin analogues (i.e., diarrhea, 
nausea, cholelithiasis, mild increase of liver enzymes, 
bradycardia, and others). At 12 months, 73% of patients 
experienced adverse events related to hyperglycemia, 
but most of the events were considered mild to 
moderate (95). These events are due to a concomitant 
inhibition of insulin, glucagon-like peptide 1 (GLP1) 
and glucose-dependent insulinotropic polypeptide 
(GIP), as well as to only a slight inhibition of glucagon 
(43,98). Thus, in addition to metformin (usually used in 
CD patients), dipeptidyl peptidase 4 (DPP4) inhibitors 
or GLP1 analogues should be the first options to treat 
hyperglycemia in this situation. Another undesired 
effect observed in a short-term study (80 days) was a 
reduction in insulin-like growth factor 1 (IGF1) levels 
to lower than normal in > 50% of patients (99). 
Adrenal steroidogenesis inhibitors
Ketoconazole
Ketoconazole is one of the most prescribed drugs for 
the treatment of CD, despite being used off label. This 
compound is an imidazole antifungal drug that reversibly 
inhibits adrenal steroidogenesis through the action of 
several enzymes (i.e., cholesterol desmolase, 17aOH 
and 11b-hydroxylase). Ketoconazole also inhibits 
androgen production resulting in hypogonadism in 
men (gynecomastia, decreased libido and erectile 
dysfunction); in women, in contrast, it might improve 
hyperandrogenism.
Two studies published in 2008 and 2014 provided 
the best assessment of ketoconazole use in CD 
(100,101). In the oldest study, 38 cases were analyzed 
and 6 series were reviewed, totalizing 99 patients. The 
series included patients who had undergone previous 
radiotherapy (102), small numbers of cases (6 – 8 cases) 
(103-107), or short-term follow-ups (range, 15 – 30 
days) (104-107). Of the 38 patients, 51.5% achieved a 
normal UFC with a mean treatment period of 22 months 
(6 – 72) and a mean dose of 529 mg/day (range, 200 
– 1000 mg). Five patients (13%) interrupted treatment 
due to side effects (nausea, diarrhea, and increased 
levels of transaminases by five-fold in one patient) 
during the first week. A few cases without visible 
tumors were primarily treated with ketoconazole. One-
third of these patients (5/15) showed visible lesions 
during follow-up (after 12 – 30 months) and were then 
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occurred in patients who already had a lesion visible by 
MRI, although the study did not report the proportion 
of micro- and macroadenomas. Similar results were 
found in the more recent multicenter retrospective 
study with a larger group of 200 patients. Normal UFC 
was observed in 49.3% of patients with mean dose of 
600 mg/day during mean time of observation of 24 
months (100). 
Another study showed similar control of disease 
activity in 9/17 patients (53%) during the preoperative 
period of patients with Cushing’s syndrome (pituitary 
or adrenal in 85% of cases) treated with 200 – 1000 
mg/day over a mean period of 4 months (108). 
Usually, treatment begins with 400 mg/day (200 mg 
twice daily; tablets: 200 mg), with the medication 
not taken near meals, as an acidic pH is needed for 
absorption. Accordingly, the use of proton pump 
inhibitors decreases drug availability. The dose is 
increased monthly, up to 1200 mg/day, to achieve UFC 
normalization, although it is uncommon to reach the 
maximum dose. Similar to cabergoline, tachyphylaxis 
may occur in up to 33% of patients following prolonged 
use of ketoconazole (101,108). Mild side effects are 
relatively common and include headache, nausea, and 
rash. Another important side effect is increased levels 
of hepatic transaminases by as much as 3 times the 
upper limit. Such increase is usually asymptomatic and 
reversible with drug interruption or dose reduction. 
Thus, it is important to monitor hepatic transaminases 
during the first month of treatment and thereafter. 
Idiosyncratic severe hepatic insufficiency has been 
described on rare occasions (19,109). 
Metyrapone
Metyrapone is used to assess the sufficiency of the 
hypothalamic-pituitary-adrenal axis and to treat 
CD. A reduction of hypercortisolism is achieved by 
blocking adrenal steroidogenesis via the inhibition 
of 11b-hydroxylase. This enzyme converts 
11-desoxicortisol (compound S) to cortisol, and 
treatment with metyrapone can result in a rebound 
of ACTH levels (73). Treatment usually begins at 
250 – 500 mg, 3 – 4 times per day, with a maximum 
dose of 4 – 6 g/day (capsules, 250 mg). In addition, 
the drug acts rapidly (from hours to days). Due to 
ACTH rebound and a shift in the production of other 
steroids, metyrapone increases androgen production 
and commonly causes hirsutism and acne. This drug 
may also cause mineralocorticoid effects, such as 
hypertension and hypokalemia. In general, short-
term studies show control of the cortisol excess in a 
significant number of patients (73). A study showed 
control in 75% of patients treated with a mean dose 
of 2250 mg/day (110). One study assessed the use of 
metyrapone during the preoperative period in patients 
with Cushing’s syndrome (85% pituitary) and showed 
UFC control in 26% of patients (6/23) treated with 750 
– 4500 mg/day for an average of 4 months (108). In 
the larger multicenter retrospective study, normal UFC 
was found in 43% of Cushing’s syndrome patients from 
all etiologies (CD, Ectopic ACTH syndrome (EAS), 
adrenal diseases) in a mean of 8 months (3 days – 12 
years) (111). Long-term studies with a large number of 
CD cases are necessary to better assess the effects of this 
drug. In addition, this drug is not available in Brazil. 
Metyrapone is currently available in USA and Europe.
Etomidate 
Etomidate is an intravenous anesthetic (imidazole 
carboxylate derivative) that decreases cortisol levels 
by inhibiting 11b-hydroxylase (112,113). The main 
advantage of etomidate is its rapid time of action, 
allowing reduction or normalization of serum cortisolin 
less than 24 hours. Thus, etomidate is useful for 
severe cases of Cushing’s syndrome, generally patients 
with ectopic ACTH syndrome (EAS). Treatment is 
performed in hospitalized patients, especially in intensive 
care units, due to clinical severity and the need for close 
monitoring, although the dose used is usually safe 
and does not cause severe sedative effects. Treatment 
assessment is primarily performed by the measurement 
of serum cortisol (113), and care should be taken to 
avoid adrenal insufficiency. ‘Block and replace’ therapy 
with hydrocortisone IV can be used. Treatment is 
performed by continuous intravenous infusion and may 
consist of an initial bolus of 0.03 mg/kg followed by 0.1 
– 0.3 mg/kg/hour (ampules, 2 mg/mL). Intermittent 
use for several hours with periodic intervals has been 
described. A review published in 2012 including 18 
studies (mostly case reports) with a total of 12 patients 
with CD found cortisol normalization in virtually all 
cases when used from 5 hours to 56 days (113). 
Mitotane
Also known as o,p’-DDD (dichloro-diphenyl-dichloro-
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patients with adrenal carcinoma. Mitotane is considered 
an adrenolytic compound due to mitochondrial 
toxicity that causes cellular necrosis. In addition, 
mitotane inhibits the adrenal production of cortisol 
by acting on enzymes involved in steroidogenesis (i.e., 
11b-hydroxylase and cholesterol desmolase) (114). 
Mitotane is a lipophilic drug, has a slower mechanism 
of action than other inhibitors, and has a very long 
half-life due to storage in adipose tissue (range, 18 – 
159 days). The established dose for the treatment of 
adrenal cancer is high (approximately 8 – 12 g/day), 
and the effective dose is verified by mitotane levels 
> 14 – 20 µg/mL. However, for the treatment of 
CD, lower, non-adrenolytic doses are prescribed, 
i.e., approximately 2 – 4 g/day (115), depending on 
the patient’s profile and UFC. Usually, treatment is 
initiated at 500 mg at bedtime, with doses increasing 
every 1 – 4 weeks (according to tolerance to treatment) 
up to 2 – 3 g/day in fractionated doses at meals 
(tablets, 500 mg). In contrast to the effective dose for 
adrenal cancer treatment, there is no target mitotane 
concentration for CD, and UFC monitoring is the most 
important parameter. In one study, mitotane levels > 
8.5 µg/mL were associated with normal UFC levels 
during follow-up (114). Use of mitotane is limited 
due to relatively common and severe side effects, such 
as nausea, vomiting, anorexia, rash, diarrhea, ataxia, 
gynecomastia, arthralgia, leukopenia, hepatotoxicity 
and hypercholesterolemia. In addition, mitotane may 
cause adrenal insufficiency, which can occasionally be 
underestimated due to an increase in cortisol binding 
globulin (CBG) levels. Due to increased corticoid 
metabolism, higher doses might be needed for adrenal 
insufficiency replacement. One study that assessed the 
use of mitotane in 76 patients with CD showed UFC 
normalization in 72% of patients with a mean treatment 
duration of 6.7 months (range, 5.2 – 8.2; mean dose, 
2.6 ± 1.1 g/day) (114). Similar to the ketoconazole 
study (101), 25% of cases without a visible pituitary 
tumor developed a visible lesion during follow-up, 
which allowed patients to undergo surgical treatment 
(114). Due to limited availability, difficult management 
and high cost, this option is rarely used in Brazil for the 
treatment of CD.
Cortisol receptor antagonist mifepristone
Mifepristone is an antiprogestogen that, at high doses, 
rapidly and competitively antagonizes the cortisol 
receptor, resulting in a rebound increase of ACTH 
and cortisol plasma levels (116). Thus, monitoring of 
mifepristone therapy in Cushing’s syndrome should be 
performed using clinical and biochemical parameters 
such as serum glucose, and not ACTH or cortisol 
levels. Mifepristone was approved in 2012 in the USA 
to control hyperglycemia (diabetes mellitus or glucose 
intolerance) in patients with endogenous Cushing’s 
syndrome (tablets, 300 mg). The approval was based 
mainly on the results of the SEISMIC trial (71), a 
prospective, multicenter, 24-week study of patients 
with endogenous Cushing’s syndrome, and diabetes 
mellitus/glucose intolerance or isolated high blood 
pressures, who were unresponsive to other therapies 
(71). The trial involved 50 patients: 43 with CD, 4 
with EAS, and 4 with adrenal carcinoma. All of the 
patients received initially 300 mg/day, and the dose 
was increased to 600, 900, and 1200 mg/day every 4 
weeks if clinical improvement was not observed. The 
primary endpoints were (i) a decrease in the area under 
the curve (AUC) of glucose of at least 25% on the 75 g 
oral tolerance test and (ii) a reduction by > 5 mmHg of 
diastolic blood pressure. With a mean dose of 600 mg/
day, improvement in glycemia (AUC) was observed in 
60% of patients (mean reduction, 36%), and the HbA1c 
levels decreased from 7.43 ± 1.52 to 6.29 ± 0.99%. 
Diastolic blood pressure improved in 38.1% of patients. 
In addition, improvements were observed in weight 
(-5.7%), waist circumference, and insulin sensitivity. 
The main side effects, primarily mild or moderate, 
were nausea, fatigue, headache, hypokalemia (effect 
of cortisol on mineralocorticoid receptor), arthralgias 
and endometrial thickening/menorrhagia. Others 
concerns about the use of mifepristone is the adrenal 
insufficiency not biochemically detected but amenable 
to be treated with high dose of dexamethasone while 
withholding mifepristone, and the possible risk of 
tumor enlargement recently published (117).
Combination therapy and perspectives 
Given that the control rate is limited with the currently 
used drugs, especially in patients with severe Cushing’s 
syndrome, combinations of different medications 
have been used as an alternative approach to control 
hypercortisolism (118). Combination therapy can 
be performed with medications from the same 
therapeutic class (e.g., combined use of steroidogenesis 
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Combined use of adrenal steroidogenesis inhibitors 
At least two recent studies assessed the effect of the 
combined use of adrenal steroidogenesis inhibitors. 
Using ketoconazole and metyrapone (doses: 200 
– 1000 mg and 750 – 4500 mg, respectively) for 
an average of 4 months (range, 1 – 30), one study 
showed control (defined as UFC, clinical parameters 
and morbidity normalization) in 23% of patients 
with Cushing’s syndrome (5/22) in the preoperative 
period (108). The second study assessed the effect 
of a triple combination of mitotane, metyrapone and 
ketoconazole as an alternative to adrenalectomy in 
11 patients with severe ACTH-dependent Cushing’s 
syndrome (UFC: 853 – 22605 µg/24 h, reference 10 
– 65), 4 patients with CD and 7 with EAS. Significant 
and rapid (24 – 48 hours) improvements in clinical 
and laboratory parameters were observed in all cases, 
with a reduction of UFC from 2737 to 50 µg/24 h 
(range, 18 – 298) and normalization achieved in 64% 
of patients. The treatment was initiated with all three 
drugs simultaneously: 2250 mg/day metyrapone, 800 
mg/day ketoconazole, and 3000 mg/day mitotane. 
The doses were adjusted according to clinical severity, 
UFC, and tolerability (119). 
Combined use of drugs targeting corticotrope tumors 
and adrenal steroidogenesis inhibitors
There is few published data concerning combined 
use of cabergoline with ketoconazole. One of the first 
studies on this subject was published in 2010 (83), 
involving 12 patients with CD (microadenomas) 
and active disease after surgical failure. The protocol 
consisted of initiating treatment with 1 mg/week 
of cabergoline (0.5 mg twice/week), with monthly 
adjustments of 1 mg/week according to UFC or up 
to 3 mg/week (1.5 mg twice/week) for 6 months. 
UFC normalization occurred in 3 patients (25%). 
In the remaining 9 uncontrolled patients, low dose 
of ketoconazole (100 mg/day) was added, with 
monthly adjustments of 100 mg or up to 400 mg/day 
(200 mg twice/day). Control was achieved in 6/9 
patients (66%) using both drugs. The remaining 
3 patients, those with higher pre-treatment UFC 
levels (range, 882 – 991 µg/24 h, reference 10–90), 
presented a lower response to cabergoline only. Thus, 
after 12 months, UFC was controlled in 75% of patients 
with cabergoline only or cabergoline + ketoconazole, 
without escapes during treatment (83). A recent 
prospective study also assessed this combination therapy 
in 14 patients with CD by comparing two different 
regimens: cabergoline followed by ketoconazole (n = 
6) vs. ketoconazole followed by cabergoline (n = 8) 
(84). Cabergoline was initiated at doses of 0.5 – 1 mg/
week up to a maximum of 3 mg with the objective 
of normalizing UFC and late-night salivary cortisol 
(NSC). Alternatively, ketoconazole was initiated at a 
dose of 200 mg/day up to a maximum dose of 600 
mg/day. Regimens were maintained for 6 months. After 
this treatment period, patients who achieved UFC and 
NSC normalization were maintained on monotherapy; 
patients with values outside of normal ranges received 
combination therapy (either with cabergoline or 
ketoconazole) for an additional 6 months. In the first 
6 months, none of the patients achieved control (UFC 
and NSC normalization) with cabergoline, although 
33% of patients (2/6) achieved UFC normalization. 
Ketoconazole monotherapy induced control in 62.5% 
of patients (5/8) at 6 months. UFC normalization 
occurred in 79% of patients who were treated with 
combination therapy, and no differences were observed 
between the two different combination regimens (84). 
Another study evaluated a triple combination 
regimen with pasireotide, cabergoline and ketoconazole 
in the preoperative period of 17 patients with CD (99), 
with the objective of normalizing UFC in 80 days. The 
treatment was initiated with 100 µg SC pasireotide, 3 
times per day, up to a maximum of 250 µg SC, 3 times 
per day. The increases were performed according to 
UFC, and the treatment continued for 30 days. After 
this period, for patients who did not achieve control, 
cabergoline was added to the treatment at a dose of 1.5 
mg/week up to a dose of 4.5 mg/week for 30 days. 
Following this period, patients who did not exhibit a 
normalized UFC in 60 days with pasireotide+cabergoline 
received ketoconazole at a dose of 600 mg/day for 20 
days. Overall, control was achieved in 29% of patients 
with pasireotide monotherapy, 47% of patients with 
pasireotide+cabergoline, and in 88% of patients with the 
triple combination. However, the achieved control of 
88% does not necessarily mean that all of these patients 
needed the triple combination. The side effects were 
worsening of HbA1c levels from 5.8±0.2 to 6.7 ± 0.3% 
(p < 0.01) and reduction of IGF1 to levels lower than 
reference in 53% (9/17) (99). Although a high rate of 
control was obtained over a short-term period, this was 
a small study with an unusual and expensive regimen 
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significative adverse events. Moreover, the outcome of 
monotherapy with cabergoline and with ketoconazole 
was not tested. For this reason, more studies enrolling 
a larger number of patients and, perhaps, exploring 
different therapeutic sequences are necessary. 
Other medications and perspectives
Temozolomide is an oral, imidazotetrazine alkylating 
chemotherapy agent used primarily for the adjuvant 
treatment of cerebral gliomas. This compound has been 
increasingly used to treat aggressive/atypical pituitary 
adenomas and pituitary carcinomas. The antitumor 
activity of temozolomide occurs through its active form, 
monomethyl-triazen-imidazole-carboxamide (MTIC), 
which promotes DNA methylation. This action can be 
neutralized by the presence of the DNA repair enzyme 
O-6-methylguanine-DNA methyltransferase (MGMT), 
an effect that can be assessed by immunohistochemistry 
or real-time reverse transcription PCR (RT-PCR) 
on tumor tissue. Although most patients who are 
responsive to temozolomide show low expression 
of MGMT, recent studies have shown some cases of 
dissociation between enzyme expression and drug 
action (120,121). Temozolomide is usually prescribed 
in monthly 5-day cycles at a dose of 200 mg/m2/
day (tablets, 5/20/100/140/180/250 mg). A 
review study showed clinical improvement (hormonal 
and tumor reduction) in 50% (4/8) of patients with 
corticotrope adenomas and in 83% (5/6) of ACTH-
producing pituitary carcinomas (122). Temozolomide 
is generally well tolerated, and the most significant side 
effects are leukopenia and thrombocytopenia. This 
medication is reserved for refractory and aggressive 
cases, not only ACTH-producing tumors, and tumor 
escape from its salutary effects may occur (121). It is 
not approved for CD in either Brazil or the USA, and 
it is rather costly.
Retinoic acid is known to have in vitro effects on 
corticotrope tumors and in an animal model of CD 
(canine) (123-125). The action of retinoic acid is likely 
mediated by a decrease in ACTH secretion and pro-
opiomelanocortin (POMC) synthesis, as demonstrated 
in a murine corticotrope cell line by the inhibition of 
POMC transcription (123). In addition, retinoic acid 
has an antiproliferative action. In a recent prospective, 
proof of concept study, 7 patients with CD were treated 
with retinoic acid (tretinoin) at a dose of 80 mg/day for 
6 – 12 months. A significant UFC reduction (> 50%) 
in 71% of patients (5/7) with normalization in 43% of 
cases (3/7) was observed (126) and the drug was well 
tolerated. Another study with 16 CD patients showed 
UFC normalization in 25% of cases with isotretinoin 
use (20-80 mg/day) for 6-12 months (127).
Other drugs have been studied in vitro and in 
animal models, showing action on corticotrope tumors 
but still lacking results in patients with CD. These 
drugs include bexarotene (retinoic acid receptor (RXR) 
agonist) (72), (a1-adrenergic receptor antagonist) 
(128) and gefitinib (EGF receptor antagonist) (129). 
Osilodrostat (LCI699) is a new developed 
steroidogenesis inhibitor. This drug was initially 
described as an aldosterone synthase inhibitor with 
potential for the treatment of hypertension (130). 
Osilodrostat is a potent inhibitor of 11b-hydroxylase 
and 18-hydroxylase (98). In a small proof-of-concept 
study, 10/11 patients with mild to severe CD achieved 
UFC normalization after 70 days of treatment with 5 – 
10 mg twice per day. The main side effects were fatigue, 
nausea, headache, and an ACTH level increase of more 
than 2-fold in 5 cases (43). More recent and prolonged 
study lasting 22 weeks observed normal UFC in 89.5% 
(17/19) of CD patients (131). 
Levoketoconazole is the 2S, 4R enantiomer of 
ketoconazole, purified from racemic ketoconazole. In 
in vitro studies, levoketoconazole was shown to be a 
more potent inhibitor than the 2R,4S enantiomer 
(132). An open-label, phase III, dose-titration study 
evaluating levoketoconazole in patients with Cushin’s 
syndrome is ongoing. 
Table 1 provides a summary of the drugs used for 
the treatment of CD.
Radiotherapy 
While used less frequently in patients with GH and 
prolactin-producing pituitary tumors, radiotherapy 
is still an important option for adjuvant or rescue 
treatment in patients with ACTH-producing tumors 
(133,134). 
Pituitary radiotherapy for CD is classically indicated 
as a secondary treatment after surgical failure. 
Radiotherapy is also used in uncontrolled patients 
receiving drug treatment, particularly those with 
residual or non-resectable tumors (e.g., cavernous 
sinus invasion). Radiotherapy is rarely used as a 
primary treatment in cases where surgical treatment 
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Table 1. Drug treatment in Cushing’s disease 
Drug Initial dose Maximum Dose Control* Duration Observations
Act on the corticotrope tumor




25-40% 18 months 
(3-60)
Escape from treatment in 18-30%;  
off label
Pasireotide 600 mg SC
2x/day
1800 mg/day 29% 12 months Frequent hyperglycemia
Steroidogenesis inhibitors
Ketoconazole 200 mg OR 
2-3x/day
1200 mg/day 52% 22 months 
(6-72)
Escape from treatment in 33%; mild 
common increase in ALT/AST;
improves hirsutism; hypogonadism in men
Metyrapone 250 mg OR 
3-4x/day
4 -6 g/day 26-75% 4 months Rebound increase of ACTH: hirsutism/
acne, HAS/hypokalemia; N/A
Etomidate IV bolus 0.03 mg/kg; 
0.1 mg/kg/h
0.3 mg/kg/h 100% 7 days 
(5 h-56 days)
Used in severe cases; hospital use 
(monitoring) 
Mitotane 500 mg OR/day 2-3 g/day 72% 7 months Frequent side effects; difficult handling; 
high cost 
Cortisol receptor antagonist
Mifepristone 300 mg OR/day 1200 mg/day 60% (glycemia 
AUC)
24 weeks Approved for the control of DM in 




200/750 mg/day 1000/4500 mg/day 23% 4 months Metyrapone N/A
Mitotane + metyrapone 
+ ketoconazole
3000/2250/800 mg/day 3000/2250/800 mg/day 100% < 6 months Critically ill patients; effect in 24-48 h
Cabergoline + 
ketoconazole




100 mg SC 3x/day/1.5 
mg/week/600 mg/day
250 mg SC 3x/day/4.5 
mg/week/600 mg/day
88% 80 days > 50% IGF1 reduction; frequent 
hyperglycemia
* Control commonly defined as the normalization of 24-hour urinary cortisol; OR: oral route; SC: subcutaneous; ALT/AST: alanine aminotransferase/aspartate aminotransferase; 
ACTH: adrenocorticotropic hormone; AUC: area under curve; DM: diabetes mellitus; IGF1: insulin-like growth factor 1; N/A: not available.
ago showed better efficacy in the pediatric population 
than in the adult population and for this reason, 
radiotherapy has been more utilized in children (135), 
although this approach is not currently accepted. In 
addition to hormonal control, another objective of 
radiotherapy is tumor mass control, either via reduction 
or stabilization/prevention of growth (i.e., the 
“oncologic” indication). Usually, the efficacy of tumor 
mass control is higher than hormonal control, ranging 
from 83% to 100% (29,134,136). 
As hormonal control is initiated at least 6 months 
after radiotherapy (mean, 18 – 24 months), there is a 
need for medical treatment in this interval (19,29,134). 
In other words, patients should not be followed without 
medication waiting for the effects of radiotherapy. In 
patients with effective concomitant clinical treatment, 
the effect of radiotherapy may be assessed by biannual 
withdrawn of drug treatment to measure cortisol 
(e.g., UFC, NSC and/or low dose dexamethasone 
suppression test (LDDST)) (19,133). 
Most data regarding the control rates and prevalence 
of complications of radiotherapy are derived from 
older studies that used conventional methods. More 
modern stereotactic radiotherapy techniques have been 
developed (i.e., fractionated or single dose), which are 
potentially more effective and induce less morbidity. 
Radiotherapy is usually performed on a well-
defined therapeutic target, particularly in the 
context of single-dose stereotactic radiotherapy (i.e., 
radiosurgery). However, it is occasionally performed 
without a clear target lesion in CD and radiation may 
encompass the entire pituitary tissue, provided that a 
diagnosis of central origin has been confirmed (e.g., 
ACTH+ pituitary adenoma, previous PO remission, 
or central to peripheral ACTH gradient at BIPSS). 
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stereotactic radiotherapy may be performed in lesions 
up to 4 cm in diameter, although it is recommended to 
allow a minimum distance in relation to optic structures 
(nerves and chiasm) of at least 3 – 5 mm. In lesions that 
are close to these structures, fractionated radiotherapy 
is safer.
Generally, hormonal control is achieved within 
2 – 5 years (mean follow-up period, 5 – 10 years) 
in approximately 50 – 60% of cases (27,29,136), 
regardless of the technique. More recent studies 
performed with radiosurgery showed a remission 
rate of approximately 50% (45,116,134,137) over 
a similar period (4 – 8 follow-up years). There is no 
good evidence of a more rapid effect of radiosurgery 
in comparison to conventional techniques (136). Some 
studies recommend drug treatment interruption during 
radiotherapy sections due to the risk of decreased 
efficacy (138), but this is a controversial issue. 
The main concern regarding radiotherapy is 
related to potential side effects. The most common is 
hypopituitarism, which occurs in over 50% of patients 
in the long-term. Other reported effects are optical 
lesions (neuritis, 1 – 2%), radionecrosis of the brain 
parenchyma (< 1%), radioinduced secondary tumors 
(1.5%) (139), neurocognitive disorders (< 1%), and 
cerebrovascular diseases (< 5%). However, stereotactic 
techniques, especially radiosurgery that is focused on 
the lesion and results in less radiation exposure to 
adjacent tissues, has shown lower complication rates 
(range, 0 – 1.3%), with the exception of hypopituitarism 
(72% in 17 years) (140). It is actually not known 
whether stereotactic radiotherapy is also associated 
with an increased risk of secondary tumors since this 
is a relatively novel treatment modality and long-term 
dara are lacking. 
Adrenalectomy
Bilateral adrenalectomy is considered a 100% 
effective hypercortisolism treatment (27,141). The 
main advantage of this method is the immediate 
normalization of cortisol levels. Currently, the surgical 
procedure is performed through a laparoscopic 
approach with reduced rate of PO complications and 
reduced time of hospitalization (141). Some cases 
may present recurrence of hypercortisolism due to a 
vicarious increase of ectopic adrenal tissue or adrenal 
residues after incomplete surgical resections (142). 
Adrenalectomy is generally indicated as the last 
therapeutic option in refractory cases following 
unsuccessfully surgical, drug and/or radiation 
treatment. This treatment may also be primarily 
indicated in severe cases of CD, for which rapid clinical 
resolution is required, as well as in patients with EAS 
(143). Finally, adrenalectomy can be performed in 
women of reproductive age who wish to become 
pregnant without hormonal stimuli and for whom 
repeated pituitary surgery and, particularly, radiotherapy 
could induce hypogonadotropic hypogonadism. One 
criticism brought up by some authors is related to 
the long time for adrenalectomy indication, exposing 
the patients for prolonged hypercortisolism and its 
catastrophic effects. This situation can be mitigated 
with treatment optimization based on rapid changes 
in the therapeutic approach, particularly with medical 
treatment. 
The disadvantages of bilateral adrenalectomy are 
permanent adrenal insufficiency with the consequent 
need of lifelong gluco- and mineralocorticoid 
replacement, the risk of acute crisis in stress situations, 
and the development of corticotrope tumor progression 
– Nelson’s Syndrome (NS) (144). 
Corticotrope tumor progression may occur 
following adrenalectomy in 21% of cases over 3 – 5 
years (145). Predictive risk factors for occurrence 
of corticotrope tumor progression are younger age, 
no previous radiotherapy, the presence of pituitary 
tumor residues or invasive tumors, higher UFC 
levels and mainly ACTH increase in the first year 
after adrenalectomy (145). However, there has been 
controversy regarding the ACTH cutoff level indicating 
increased risk. Some authors suggested that an increase 
of plasma ACTH levels ≥ 600 or ≥ 1000 pg/mL on 
the first year after adrenalectomy might indicate tumor 
progression (144,146). Due to inconsistent data, 
radiotherapy has not been used as prophylaxis, especially 
with available pituitary MRI imaging and ACTH 
measurements that are systematically assessed during 
the follow-up in order to identify corticotrope tumor 
progression. Interestingly, although the suggested risk 
of corticotroph tumor progression has been around 
50% (140), many of these patients do not develop 
clinical features of Nelson’s syndrome with mass effect 
or skin hyperpigmentation. Thus, is seems that clinical 
Nelson’s syndrome is less common than corticotroph 
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Finally, an old study compared remission rate 
of pituitary surgery with a unilateral adrenalectomy 
protocol associated with conventional primary pituitary 
radiotherapy. This report found a similar result of 64% 
remission of both strategies (142). However, due to 
the absence of similar data and a lack of improved 
surgical remission rates, the clinical applicability of this 
approach is limited. 
Pregnancy
Pregnancy during active CD is very rare and difficult 
to handle. The reason for the low prevalence is that 
hypercortisolism interferes with fertility, particularly 
due to changes in LH/FSH pulsatility, causing 
menstrual changes/amenorrhea and anovulation. In 
addition, an increase in androgen production usually 
occurs due to ACTH stimulation, which inhibits the 
normal dynamics of gonadotropins. Perhaps, for this 
reason, most pregnant patients with CD are carriers of 
adrenal adenomas (40 – 50%) (147-150).
Although rare, the identification and correct 
treatment of this condition is important due to the 
increased risk of materno-fetal complications (> 70%) 
(147,148). 
The most common treatment approaches are 
pituitary surgery, medical therapy, and bilateral 
adrenalectomy. Expectant approach is also possible when 
the Cushing’s syndrome diagnosis is made at the end of 
pregnancy, with careful management of associated co-
morbidities, such as hypertension and diabetes (148). 
When treatment is indicated, it is usually performed 
during or after the second trimester due to the time 
needed to establish the diagnosis. During the gestation 
period, most pituitary surgeries have a good outcome, 
and for this reason, pituitary surgery should be the first 
treatment of choice. Alternatively, during or after the 
second trimester, drug treatment may be chosen. In this 
case, metyrapone has been the most reported drug but 
it is not available in Brazil. The use of has been reported 
in few cases without the occurrence of congenital 
malformations (96). However, ketoconazole has been 
shown to be teratogenic in animal studies and should 
only be used when metyrapone is not available or induces 
side effects. There is a single report of cabergoline use in 
a pregnant patient with CD (151). In more severe and 
unresponsive cases, as well as in adrenal-related disease, 
adrenalectomies have been performed in several patients 
(147,148) and are generally effective.
Table 2 summarizes indications for therapeutic 
options in CD, and Figure 1 shows a proposed 
treatment algorithm. 
Role of the authors: the authors of this review comprise an expert 
committee that was gathered in order to provide an updated review 
of the treatment of Cushing’s disesase through the contribution of 
each author.
Review methods: The lead author performed a PubMed search of 
CD treatment and discussed with the senior author. The review 
was then drafted and circulated to the members of the committee 
who provided with numerous contributions to the final text.
Disclosure: no potential conflict of interest relevant to this article 
was reported.
Table 2. Therapeutic options in Cushing’s disease 
Type Control* Advantage Disadvantage Observations




Rapid; direct Lower remission in invasive macros, 
and when tumor not visible in image
General treatment of choice
Subsequent pituitary surgery 40 – 70% Possibility of definitive resolution Lower remission compared to first 
surgery; increases the risk of 
cerebrospinal fluid fistula and 
hypopituitarism
Best suited for patients with 
persistence of tumoral image
Drug treatment 40 – 100% Noninvasive; allows patients to 
undergo surgery if needed 
Chronic use; side effects Mainly indicated in surgical failure, 
and after RTX
Stereotactic radiotherapy 50 – 60% Direct treatment Slow start; side effects 
(hypopituitarism) 
Associated with drug treatment
Bilateral adrenalectomy 100% Immediate control Risk of corticotrope tumor 
progression; permanent gluco- and 
mineralocorticoid insufficiency
Indicated in severe cases, refractory 
cases, and when pregnancy is 
desired
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CUSHING’S DISEASE ESTABLISHED DIAGNOSIS* 
TRANSSPHENOIDAL PITUITARY SURGERY 
- Microadenomas 
- Macroadenomas without invasion 
- Macroadenomas with invasion (debulking) 
- Visual compression 
DRUG TREATMENT 
- Monotherapy: cabergoline or ketoconazole 
- Combined (cabergoline + ketoconazole) or other drug 
REMISSION 
- Periodic assessment of recurrence 
(first-line tests) 
NEW PITUITARY SURGERY 
- Pituitary image persistence 
- ACTH+ pituitary adenoma (first surgery) 
NO CONTROL 
RADIOTHERAPY 
- Medical treatment associated 
ADRENALECTOMY 
NO REMISSION OR 
RECURRENCE 
     CONTROL 
- Monitor scape and MRI 
- Consider RTX 
NO REMISSION OR 
RECURRENCE 
Figure 1. Treatment algorithm for the treatment of Cushing’s disease. 
* Primary clinical treatment may be considered in patients with a contraindication to surgery, those who need to improve preoperative clinical conditions, those who refuse surgical treatment, and 
in case an experienced surgeon is unavailable. Pituitary surgery should be performed in tertiary centers by experienced surgeons, and patient referral should be considered when these conditions 
cannot be achieved. Very severe cases may undergo initial bilateral adrenalectomy.
RTX: pituitary radiotherapy.
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